-
Crew splashes down after 8-month mission on International Space Station
-
Ex-prince Andrew raid warrants ruled 'unlawful' but UK police maintain probe
-
Protests, clashes as S. African anti-migrant tensions reignite
-
Two Latvians arrested inside UK military base: police
-
Russian data centre hit by drone in first for Ukraine war
-
Eckert 'forever grateful' for Southampton support over spy scandal
-
'Fighting for our future': France high school students vow no let-up
-
Venezuela's Maduro, wife hit with new US torture charges
-
Kyiv entering 'survival' mode amid Russian strikes surge: mayor tells AFP
-
Argentina friendlies no fairy tale for African footballers
-
Verdict due in Mexico trial over murders of Australia, US surfers
-
US suspending Microsoft from visa program: Vance
-
B2PRIME Welcomes Christina Barbash as Commercial Manager
-
Man City must 'stick together' during crisis, says Haaland
-
Russia forcing Kyiv into 'survival' mode before winter, mayor tells AFP
-
CAS opens hearing into Senegal AFCON title appeal
-
Closing arguments begin in Maradona death trial
-
UK police agree searches for ex-prince Andrew's homes 'unlawful': judge
-
UEFA president Ceferin to stand for re-election in 2027
-
After botched US execution, Christa Pike walking, mentally 'foggy': lawyer
-
Nearly 300,000 Nepalis at flood risk: study
-
'Stunned' Madrid mourns pensioner who sparked housing protests
-
Riyadh kindergarten hit by interception debris as Houthis say targeted airport
-
High school students turn out for new protests across France
-
Alex Bodi mizează, alături de CRIF, pe investiții transparente și pe prevenirea riguroasă a spălării banilor
-
Bid by Italy's Intesa bank to take over MPS gets boost
-
Gulf Labs, Part of Thailand’s $27 Billion GULF Group, Goes Live as an Injective Validator
-
Stablecoins Are Quietly Becoming Business Infrastructure, NOWPayments Data Shows
-
EU okay for winter despite 'historically low' gas stocks: operators
-
Oil surges, stocks sink as US reportedly eyes new Iran strikes
-
Rwanda to host F1 Grand Prix: sources close to both sides
-
Woman in botched US execution walking, mentally 'foggy': lawyer
-
EU top diplomat says bloc in favour of UN Lebanon peacekeepers' extension
-
Farhan hopes Pakistan's new combination takes off in Sri Lanka T20Is
-
Antonelli and Russell to run different Mercedes aero packages in Singapore
-
Teenager Andreeva seals China Open semi-final with Bartunkova
-
WTO hikes 2026 trade growth forecast on AI boom
-
Britain's Burnham says open to Germany joining warplane project
-
'I love that challenge': Hamilton prays for rain in Singapore
-
Kovac's tough love has Dortmund dreaming of title charge
-
G.Bissau moves towards postponement of December general election
-
China announces candidate for WHO chief
-
Verstappen out to settle 'unfinished business' at Singapore Grand Prix
-
South Korea test-fires its first homegrown hypersonic weapon: presidency
-
WhiteBIT Launches Bitcoin Lightning Network Support, Powered by Voltage
-
ONAR Advances Nasdaq Listing Preparation Following Advertise Purple Acquisition and Financing
-
Oil surges, stocks sink as US reportedly eyes fresh Iran strikes
-
Thailand opens extradition process for reporter sought by China
-
Anne Carson: modern takes on Greek classics
-
France struggles to wean social housing off gas
Trump signs order to fast-track research on psychedelic drugs
US President Donald Trump on Saturday announced an easing of restrictions on research into psychedelic drugs -- such as so-called "magic mushrooms" -- that have shown promise in treating people with mental health conditions.
Flanked by US Health Secretary Robert F. Kennedy Jr, top medical officials and podcaster Joe Rogan, who has pushed for access to the drugs, Trump signed an executive order that would help federal researchers cut through the red tape to allow for quicker studies.
The president said the order would "clear away unnecessary bureaucratic hurdles, improve data sharing among the FDA (Food and Drug Administration) and the Department of Veterans Affairs and facilitate fast rescheduling of any psychedelic drugs that become FDA approved."
Currently, many psychedelics including LSD and psilocybin ("magic mushrooms") are classified -- or "scheduled" -- as having high abuse and addiction potential, and are not approved for medical use, limiting the ability for scientists to study them.
If the FDA, which is charged with regulating pharmaceuticals in the United States, officially finds a medical benefit for some of the psychedelics, they could be rescheduled, allowing for greater clinical use.
The order only provides for accelerated research and does not immediately require law enforcement authorities to reclassify the drugs, meaning therapeutic use will not expand immediately.
In recent years, there has been a growing push to research the effects of the drugs in treating people -- especially war veterans -- with difficult anxiety and depression cases, especially those who had experienced traumatic stress.
Many veterans and other patients have complained that traditional antidepressant cocktails not only fail to work but change their personalities in ways that alienate them from their friends and family.
In 2023, 6,398 veterans took their own lives, the Department of Veterans Affairs said.
During the signing ceremony at the White House, Trump pointed to one drug called ibogaine, claiming patients who had taken it "experienced an 80 to 90 percent reduction in symptoms of depression and anxiety within one month."
"Can I have some, please?" he joked.
The full extent of the benefits and potential side effects of psychedelic medications is not yet known, since research has been restricted.
While many are thought to show promising mental health benefits, there are risks. Ibogaine, for instance, is thought to potentially damage the heart.
If you are a US veteran in need of help, or concerned about one, you can dial 988 and press 1, or visit www.veteranscrisisline.net.
J.Bergmann--BTB